How Is the Middle East and Africa CDMO Market Evolving Amid Rising Biopharma Demand?

The Middle East and Africa CDMO Market is undergoing structural expansion driven by rising disease prevalence, increasing oncology burden, and government-led pharmaceutical localization initiatives across key economies such as Saudi Arabia, the UAE, South Africa, and Nigeria.

The Middle East and Africa CDMO Market was valued at USD 9.95 Billion in 2025 and is projected to reach USD 17.00 Billion by 2035, expanding at a CAGR of 5.50% (2026–2035). This growth reflects accelerating outsourcing trends in pharmaceutical manufacturing and research, particularly as global biopharma firms diversify supply chains beyond traditional hubs.

The Middle East and Africa CDMO Market (Contract Development and Manufacturing Organization market) encompasses outsourced services including API manufacturing, finished dosage formulation, clinical research, and packaging services that support pharmaceutical and biopharmaceutical companies across the drug lifecycle.

Strategically, the Middle East and Africa CDMO Market is becoming a critical extension of global pharma supply chains due to cost advantages, regulatory modernization, and increasing investment in regional healthcare infrastructure.

What is the Middle East and Africa CDMO Market and Why Does It Matter?

The Middle East and Africa CDMO Market refers to outsourced pharmaceutical development and manufacturing services provided to drug developers, including both chemical (small molecule) and biologics production.

It matters because it enables:

• Faster drug development timelines
• Reduced capital expenditure for pharma companies
• Scalable manufacturing capacity for emerging markets
• Access to specialized expertise in oncology and biologics

The Middle East and Africa CDMO Market is also strategically important due to rising demand for localized drug production, especially in response to supply chain disruptions observed during global health crises.

What is the Current Market Size and Growth Outlook of the Middle East and Africa CDMO Market?

The Middle East and Africa CDMO Market demonstrates steady mid-single-digit growth driven by pharmaceutical outsourcing and healthcare expansion.

• 2025 Market Size: USD 9.95 Billion
• 2035 Forecast: USD 17.00 Billion
• CAGR (2026–2035): 5.50%

Growth is supported by:

• Expansion of oncology drug pipelines
• Increased biologics production outsourcing
• Government-backed pharmaceutical localization programs

The Middle East and Africa CDMO Market is transitioning from a cost-efficient outsourcing hub to a strategic pharmaceutical manufacturing region.

What Are the Primary Growth Drivers of the Middle East and Africa CDMO Market?

1. Rising Disease Burden and Oncology Demand

The increasing prevalence of cancer and chronic diseases is a key driver. Oncology remains the largest therapeutic focus in the Middle East and Africa CDMO Market.

2. Government-Led Localization Policies

Countries such as Saudi Arabia and the UAE are investing heavily in domestic pharmaceutical production capacity to reduce import dependency.

3. Global Pharma Outsourcing Expansion

Major pharmaceutical companies are increasingly outsourcing R&D and manufacturing to optimize cost structures and scale operations.

4. Biologics and Complex Molecule Growth

The shift toward biologics and high-potency APIs (HPAPIs) is accelerating CDMO demand in the region.

What Challenges Are Restricting the Middle East and Africa CDMO Market?

Despite strong growth potential, the Middle East and Africa CDMO Market faces structural constraints:

Infrastructure Gaps

Limited advanced manufacturing infrastructure in several African markets restricts scale efficiency.

Regulatory Fragmentation

Diverse regulatory frameworks across countries increase compliance complexity.

Skilled Workforce Shortage

A shortage of specialized biopharma talent limits rapid industry scaling.

Capital Intensity

High investment requirements for biologics and sterile manufacturing facilities slow expansion.

What Emerging Trends Are Reshaping the Middle East and Africa CDMO Market?

1. Biologics and Biosimilars Expansion

The Middle East and Africa CDMO Market is witnessing rapid growth in biologics manufacturing, driven by global demand for complex therapies.

2. Oncology-Centric Manufacturing Pipelines

Oncological diseases dominate therapeutic demand, influencing CDMO capacity allocation.

3. Digitalized Clinical Research Operations

Contract Research Organizations (CROs) are increasingly adopting digital trial management systems.

4. Strategic Global Partnerships

Companies such as Lonza Group and Boehringer Ingelheim are expanding collaboration networks in emerging regions.

Middle East and Africa CDMO Market Segmentation Analysis

By Service Type

• Contract Manufacturing Organization (CMO)
• Active Pharmaceutical Ingredient (API) Manufacturing
  • Small Molecule
  • Large Molecule
  • High Potency APIs (HPAPI)
• Finished Dosage Formulation (FDF)
  • Solid Dose
  • Liquid Dose
  • Injectable
• Contract Research Organization (CRO)
  • Phase I–IV Clinical Trials
• Secondary Packaging Services

API manufacturing and injectable formulation segments are the fastest-growing within the Middle East and Africa CDMO Market.

By Therapeutic Area

• Oncology (dominant segment)
• Metabolic Disorders
• Neurological Disorders
• Infectious Diseases
• Cardiovascular Diseases
• Respiratory Diseases

Oncology remains the core demand driver due to rising regional cancer incidence.

By End User

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Medical Device Companies

Pharmaceutical and biopharmaceutical firms account for the majority of outsourcing demand.

Regional Analysis of the Middle East and Africa CDMO Market

Saudi Arabia

• Strongest government-led pharmaceutical localization initiatives
• Rapid expansion of healthcare manufacturing zones

United Arab Emirates

• Emerging biotech investment hub
• Strategic logistics and re-export advantage

South Africa

• Most developed pharmaceutical ecosystem in Africa
• Strong clinical trial infrastructure

Nigeria

• High population-driven demand
• Developing regulatory framework

Others

• Fragmented but high-growth potential across North and Sub-Saharan Africa

The Middle East and Africa CDMO Market is increasingly bifurcated between high-investment Gulf economies and emerging African healthcare systems.

Competitive Landscape of the Middle East and Africa CDMO Market

The Middle East and Africa CDMO Market is dominated by global CDMO leaders expanding through partnerships, acquisitions, and regional capacity building.

Key players include:

• Lonza Group
• Thermo Fisher Scientific Inc. (Patheon Pharma Services)
• Pfizer Inc.
• WuXi AppTec
• WuXi Biologics
• FUJIFILM Diosynth Biotechnologies
• Fareva SA
• B. Braun SE

Strategic Market Positioning

• Western CDMOs dominate high-end biologics and HPAPI production
• Asian players lead in cost-efficient large-scale manufacturing
• Regional MEA facilities are increasingly focused on fill-finish and secondary packaging

Recent Strategic Developments

• Expansion of biologics capacity in emerging markets
• Partnerships between global CDMOs and regional healthcare authorities
• Investment in oncology-focused manufacturing infrastructure

Regulatory and Policy Landscape

The Middle East and Africa CDMO Market is shaped by evolving regulatory frameworks:

Global Standards Alignment

• Increasing alignment with FDA and EMA guidelines in major regional hubs

Regional Regulatory Differences

• Gulf Cooperation Council (GCC) countries exhibit faster regulatory modernization
• African nations face heterogeneous regulatory maturity levels

Policy Drivers

• Import substitution policies
• Pharmaceutical localization mandates
• Public-private healthcare investment programs

Future Outlook of the Middle East and Africa CDMO Market (2026–2035)

The Middle East and Africa CDMO Market is expected to evolve into a strategically important extension of global pharmaceutical supply chains.

Key Future Drivers:

• Expansion of biologics and cell therapy manufacturing
• Growth of oncology-focused drug pipelines
• Increased outsourcing by global pharmaceutical firms
• Infrastructure modernization in GCC and select African economies

Investment Attractiveness:

High potential in:

• Biologics manufacturing facilities
• API production hubs
• Clinical trial outsourcing services

Innovation Outlook:

• AI-enabled drug development workflows
• Automated manufacturing systems
• Decentralized clinical trial models

By 2035, the Middle East and Africa CDMO Market will shift from an emerging outsourcing region to a strategic global biopharma production node.

Uncover More Reports

Genomics Market

Legal Marijuana Market

Telemedicine Market

Skincare Devices Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com